{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T10:01:59Z","timestamp":1782986519650,"version":"3.54.5"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.josat.2025.209623","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T19:25:22Z","timestamp":1737746722000},"page":"209623","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Perceived organizational support for the treatment of opioid use disorder and its association with primary care provider treatment willingness and medication prescribing"],"prefix":"10.1016","volume":"171","author":[{"given":"Lindsay Y.","family":"Dhanani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Go","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet E.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berkeley","family":"Franz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.josat.2025.209623_bb0005","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1080\/00952990.2021.1979991","article-title":"The impact of relaxation of methadone take-home protocols on treatment outcomes in the COVID-19 era","volume":"47","author":"Amram","year":"2021","journal-title":"American Journal of Drug and Alcohol Abuse"},{"issue":"4","key":"10.1016\/j.josat.2025.209623_bb0010","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1370\/afm.2099","article-title":"Barriers rural physicians face prescribing buprenorphine for opioid use disorder","volume":"15","author":"Andrilla","year":"2017","journal-title":"Annals of Family Medicine"},{"issue":"1","key":"10.1016\/j.josat.2025.209623_bb0015","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/jrh.12328","article-title":"Overcoming barriers to prescribing buprenorphine for the treatment of opioid use disorder: Recommendations from rural physicians","volume":"35","author":"Andrilla","year":"2019","journal-title":"The Journal of Rural Health"},{"key":"10.1016\/j.josat.2025.209623_bb0020","author":"Centers for Disease Control and Prevention","year":"2022","journal-title":"Underlying cause of death 1999\u20132021"},{"issue":"1","key":"10.1016\/j.josat.2025.209623_bb0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11414-014-9419-6","article-title":"The impact of technical assistance and implementation support on program capacity to deliver integrated services","volume":"43","author":"Chaple","year":"2016","journal-title":"Journal of Behavioral Health Services and Research"},{"key":"10.1016\/j.josat.2025.209623_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108395","article-title":"The integrating medications for addiction treatment (IMAT) index: A measure of capability at the organizational level","volume":"126","author":"Chokron Garneau","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1","key":"10.1016\/j.josat.2025.209623_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1748-5908-4-50","article-title":"Fostering implementation of health services research findings into practice: A consolidated framework for advancing implementation science","volume":"4","author":"Damschroder","year":"2009","journal-title":"Implementation Science"},{"key":"10.1016\/j.josat.2025.209623_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ssmmh.2023.100263","article-title":"Positive contact and empathy as predictors of primary care providers\u2019 willingness to prescribe medications for opioid use disorder","volume":"4","author":"Dhanani","year":"2023","journal-title":"SSM - Mental Health"},{"issue":"16","key":"10.1016\/j.josat.2025.209623_bb0045","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1001\/jama.2015.3474","article-title":"Emergency department-initiated buprenorphine\/naloxone treatment for opioid dependence: A randomized clinical trial","volume":"313","author":"D\u2019Onofrio","year":"2015","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.josat.2025.209623_bb0050","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.14045","article-title":"Monthly patient volumes of buprenorphine-waivered clinicians in the US","volume":"3","author":"Duncan","year":"2020","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2025.209623_bb0055","article-title":"Opioid Use Disorder","author":"Dydyk","year":"2023","journal-title":"StatPearls"},{"key":"10.1016\/j.josat.2025.209623_bb0060","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.drugalcdep.2014.03.006","article-title":"The impact of buprenorphine\/naloxone treatment on HIV risk behaviors among HIV-infected","volume":"139","author":"Edelman","year":"2014","journal-title":"Opioid-Dependent Patients. Drug and Alcohol Dependence"},{"issue":"5","key":"10.1016\/j.josat.2025.209623_bb0065","doi-asserted-by":"crossref","first-page":"735","DOI":"10.15288\/jsad.2017.78.735","article-title":"Promoting adoption of medication for opioid and alcohol use disorders through system change","volume":"78","author":"Ford","year":"2017","journal-title":"Journal of Studies on Alcohol and Drugs"},{"key":"10.1016\/j.josat.2025.209623_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108811","article-title":"Primary care physicians\u2019 preparedness to treat opioid use disorder in the United States: A cross-sectional survey","volume":"225","author":"Foti","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"issue":"1","key":"10.1016\/j.josat.2025.209623_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13722-021-00242-w","article-title":"Physician blame and vulnerability: Novel predictors of physician willingness to work with patients who misuse opioids","volume":"16","author":"Franz","year":"2021","journal-title":"Addiction Science & Clinical Practice"},{"issue":"1","key":"10.1016\/j.josat.2025.209623_bb0080","first-page":"1","article-title":"Buprenorphine misinformation and willingness to treat patients with opioid use disorder among primary care-aligned health care professionals","volume":"19","author":"Franz","year":"2024","journal-title":"Addiction Science & Clinical Practice 2024 19:1"},{"issue":"1","key":"10.1016\/j.josat.2025.209623_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12954-023-00918-3","article-title":"Differences in buprenorphine prescribing readiness among primary care professionals with and without X-waiver training in the US","volume":"20","author":"Franz","year":"2023","journal-title":"Harm Reduction Journal"},{"issue":"8","key":"10.1016\/j.josat.2025.209623_bb0090","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1080\/10826084.2022.2079133","article-title":"The role of misinformation and stigma in opioid use disorder treatment uptake","volume":"57","author":"Garett","year":"2022","journal-title":"Substance Use & Misuse"},{"issue":"2","key":"10.1016\/j.josat.2025.209623_bb0095","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1037\/a0022776","article-title":"Facilitators and barriers in implementing buprenorphine in the veterans health administration","volume":"25","author":"Gordon","year":"2011","journal-title":"Psychology of Addictive Behaviors: Journal of the Society of Psychologists in Addictive Behaviors"},{"issue":"2","key":"10.1016\/j.josat.2025.209623_bb0100","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s11414-012-9317-8","article-title":"Assessing the co-occurring capability of mental health treatment programs: The dual diagnosis capability in mental health treatment (DDCMHT) index","volume":"40","author":"Gotham","year":"2013","journal-title":"Journal of Behavioral Health Services and Research"},{"issue":"3","key":"10.1016\/j.josat.2025.209623_bb0105","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jsat.2013.09.002","article-title":"A qualitative study of the adoption of buprenorphine for opioid addiction treatment","volume":"46","author":"Green","year":"2014","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"4","key":"10.1016\/j.josat.2025.209623_bb0110","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.0887-378X.2004.00325.x","article-title":"Diffusion of innovations in service organizations: Systematic review and recommendations","volume":"82","author":"Greenhalgh","year":"2004","journal-title":"The Milbank Quarterly"},{"key":"10.1016\/j.josat.2025.209623_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108223","article-title":"Re-thinking patient stability for methadone in opioid treatment programs during a global pandemic: Provider perspectives","volume":"124","author":"Hatch-Maillette","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2025.209623_bb0120","article-title":"(RE-)AIMing for rapid uptake","author":"Heavey, S. C., Beehler, G. P., & Funderburk, J","year":"2023","journal-title":"Medical Care"},{"issue":"2","key":"10.1016\/j.josat.2025.209623_bb0125","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1037\/0033-2909.93.2.388","article-title":"A random effects model for effect sizes","volume":"93","author":"Hedges","year":"1983","journal-title":"Psychological Bulletin"},{"issue":"1","key":"10.1016\/j.josat.2025.209623_bb0130","first-page":"1","article-title":"A randomized controlled trial of an intervention to reduce stigma toward people with opioid use disorder among primary care clinicians","volume":"18","author":"Hooker","year":"2023","journal-title":"Addiction Science & Clinical Practice 2023 18:1"},{"issue":"2","key":"10.1016\/j.josat.2025.209623_bb0135","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1370\/afm.1595","article-title":"Barriers to primary care physicians prescribing buprenorphine","volume":"12","author":"Hutchinson","year":"2014","journal-title":"The Annals of Family Medicine"},{"issue":"7","key":"10.1016\/j.josat.2025.209623_bb0140","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s11606-021-07355-7","article-title":"Champions among us: Leading primary care to the forefront of opioid use disorder treatment","volume":"37","author":"Incze","year":"2022","journal-title":"Journal of General Internal Medicine"},{"issue":"4","key":"10.1016\/j.josat.2025.209623_bb0145","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11414-020-09706-4","article-title":"Organizational facilitators and barriers to medication for opioid use disorder capacity expansion and use","volume":"47","author":"Jacobson","year":"2020","journal-title":"The Journal of Behavioral Health Services & Research"},{"key":"10.1016\/j.josat.2025.209623_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103786","article-title":"Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019\u2033","volume":"110","author":"Krawczyk","year":"2022","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.josat.2025.209623_bb0155","doi-asserted-by":"crossref","DOI":"10.1177\/21501319221112272","article-title":"Buprenorphine waiver attitudes among primary care providers","volume":"13","author":"Lai","year":"2022","journal-title":"Journal of Primary Care & Community Health"},{"issue":"1","key":"10.1016\/j.josat.2025.209623_bb0160","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/ADM.0b013e318276e7a4","article-title":"Organizational capacity to address co-occurring substance use and psychiatric disorders: Assessing variation by level of care","volume":"7","author":"Lambert-Harris","year":"2013","journal-title":"Journal of Addiction Medicine"},{"issue":"5","key":"10.1016\/j.josat.2025.209623_bb0165","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.12419","article-title":"Survey of barriers and facilitators to prescribing buprenorphine and clinician perceptions on the drug addiction treatment act of 2000 waiver","volume":"5","author":"Lanham","year":"2022","journal-title":"JAMA Network Open"},{"issue":"10118","key":"10.1016\/j.josat.2025.209623_bb0170","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"The Lancet"},{"issue":"Suppl. 3","key":"10.1016\/j.josat.2025.209623_bb0175","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s11606-020-06257-4","article-title":"Barriers and facilitators to the use of medications for opioid use disorder: A rapid review","volume":"35","author":"Mackey","year":"2020","journal-title":"Journal of General Internal Medicine"},{"key":"10.1016\/j.josat.2025.209623_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2009.03.001","article-title":"Understanding the importance of organizational and system variables on addiction treatment services within criminal justice settings","author":"McCarty","year":"2009","journal-title":"Drug and Alcohol Dependence"},{"issue":"7","key":"10.1016\/j.josat.2025.209623_bb0185","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1176\/ps.2007.58.7.949","article-title":"Co-occurring psychiatric and substance use disorders: A multistate feasibility study of the quadrant model","volume":"58","author":"McGovern","year":"2007","journal-title":"Psychiatric Services"},{"issue":"4","key":"10.1016\/j.josat.2025.209623_bb0190","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jsat.2012.08.013","article-title":"Development and initial feasibility of an organizational measure of behavioral health integration in medical care settings","volume":"43","author":"McGovern","year":"2012","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1","key":"10.1016\/j.josat.2025.209623_bb0195","doi-asserted-by":"crossref","DOI":"10.1186\/s12875-017-0673-6","article-title":"Assessing and improving organizational readiness to implement substance use disorder treatment in primary care: Findings from the SUMMIT study","volume":"18","author":"Ober","year":"2017","journal-title":"BMC Family Practice"},{"key":"10.1016\/j.josat.2025.209623_bb2200","unstructured":"Opioid & Health Indicators Database. Accessed July 15, 2024. https:\/\/opioid.amfar.org\/about\/download."},{"issue":"1","key":"10.1016\/j.josat.2025.209623_bb0205","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/0091217420946240","article-title":"Facilitators and barriers to utilization of medications for opioid use disorder in primary care in South Carolina","volume":"56","author":"Oros","year":"2021","journal-title":"International Journal of Psychiatry in Medicine"},{"issue":"2","key":"10.1016\/j.josat.2025.209623_bb0210","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/15504263.2013.778441","article-title":"Dual diagnosis capability in mental health and substance use disorder treatment programs","volume":"9","author":"Padwa","year":"2013","journal-title":"Journal of Dual Diagnosis"},{"key":"10.1016\/j.josat.2025.209623_bb0215","article-title":"Measures of organizational culture, organizational climate, and implementation climate in behavioral health: A systematic review","volume":"2","author":"Powell","year":"2021"},{"key":"10.1016\/j.josat.2025.209623_bb0220","author":"SAMHSA"},{"key":"10.1016\/j.josat.2025.209623_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.amepre.2023.01.037","article-title":"Buprenorphine after nonfatal opioid overdose: Reduced mortality risk in Medicare disability beneficiaries","author":"Samples","year":"2023","journal-title":"American Journal of Preventive Medicine"},{"key":"10.1016\/j.josat.2025.209623_bb0230","first-page":"361","volume":"64","author":"Schneider","year":"2013","journal-title":"Organizational Climate and Culture"},{"key":"10.1016\/j.josat.2025.209623_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2022.108900","article-title":"Not in my treatment center: Leadership\u2019s perception of barriers to MOUD adoption","volume":"144","author":"Stewart","year":"2023","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1","key":"10.1016\/j.josat.2025.209623_bb0240","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jsat.2007.08.004","article-title":"Buprenorphine\/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors","volume":"35","author":"Sullivan","year":"2008","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2025.209623_bb0245","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.drugalcdep.2017.10.002","article-title":"Prescribing patterns of buprenorphine waivered physicians","volume":"181","author":"Thomas","year":"2017","journal-title":"Drug and Alcohol Dependence"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875925000025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875925000025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T20:57:31Z","timestamp":1777323451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875925000025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":49,"alternative-id":["S2949875925000025"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2025.209623","relation":{},"ISSN":["2949-8759"],"issn-type":[{"value":"2949-8759","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perceived organizational support for the treatment of opioid use disorder and its association with primary care provider treatment willingness and medication prescribing","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2025.209623","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"209623"}}